The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciy279 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simulated Target Attainment of Multidose Regimens of Dalbavancin for Prolonged Durations of Therapy.
Open Forum Infect Dis
June 2024
Pharmacy Practice and Translational Research Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Background: Dalbavancin is a long-acting lipoglycopeptide antibiotic that is increasingly utilized for infections that require prolonged treatment durations despite the lack of Food and Drug Administration approval for these indications. There is no consensus regarding optimal dosing of dalbavancin for these infections and no available pharmacokinetic studies to identify optimal dosing for long-term use.
Methods: An in silico pharmacokinetic simulation was performed to assess the predicted dalbavancin concentration resulting from commonly utilized dosing regimens, in addition to modified regimens.
Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience.
Rev Esp Quimioter
August 2024
David Brandariz-Núñez, Pharmacy Department, Universitary Complex Hospital A Coruña (CHUAC). A Coruña, Spain.
Objective: Infective endocarditis (IE) is a potentially life-threatening infection, the incidence of which has in creased in recent decades, particularly among elderly patients with comorbidity. The primary objective of this study was to evaluate the effectiveness of dalbavancin in the consolidation therapy of IE in patients with comorbidity six months after the end of treatment (EOT).
Methods: An observational and retrospective study was conducted on patients with a Charlson Comorbidity Index (CCI) ≥ 3 who were diagnosed with IE and received consolidation therapy with dalbavancin.
Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
Int J Antimicrob Agents
June 2024
Department of Pharmacy, Huntsville Hospital, Huntsville, AL.
Background: Oritavancin and dalbavancin are long-acting lipoglycopeptide antibiotics approved for the treatment of skin and skin structure infections. Recently, they have been used for outpatient antimicrobial therapy for complicated infections. No head-to-head studies exist for this purpose.
View Article and Find Full Text PDFCost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections.
Am J Health Syst Pharm
May 2024
Department of Pharmacy, University of Rochester Medical Center: Strong Memorial Hospital, Rochester, NY, USA.
Purpose: Persons who inject drugs (PWID) are at risk for severe gram-positive infections and may require prolonged hospitalization and intravenous (IV) antibiotic therapy. Dalbavancin (DBV) is a long-acting lipoglycopeptide that may reduce costs and provide effective treatment in this population.
Methods: This was a retrospective review of PWID with severe gram-positive infections.
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
Infect Dis Ther
March 2024
Wayne State University, Detroit, MI, USA.
Introduction: Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly in those with barriers to discharge or who require prolonged parenteral antibiotic courses. A retrospective cohort study was performed to provide further multicenter real-world evidence on dalbavancin use as a sequential therapy for Gram-positive BSI.
Methods: One hundred fifteen patients received dalbavancin with Gram-positive BSI, defined as any positive blood culture or diagnosed with infective endocarditis, from 13 centers geographically spread across the United States between July 2015 and July 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!